{"groups":[{"description":"Patients receive afatinib dimaleate 40mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAfatinib Dimaleate: Given PO","id":"FG000","title":"Treatment (Afatinib Dimaleate)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Never Started Treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"27"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Alternative Therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Increased Tumor Burden"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Symptomatic Detrioration"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"40"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"39"}],"type":"Eligible"},{"achievements":[{"groupId":"FG000","numSubjects":"37"}],"comment":"One patient ineligible, 2 patients never started treatment. This is the primary analysis population.","type":"Eligible and Started Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"37"}],"comment":"Excluding two who did not receive afatinib treatment and one who was not assessed for toxicity","type":"Reported Adverse Events Data"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"comment":"Treatment continued until disease progression or intolerability.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"40"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"To be assigned to a specific MATCH subprotocol, patients needed to submit a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial entered corresponding MATCH subprotocol. For the subprotocol B, patients had to have a qualifying ERBB2 actionable mutation.","recruitmentDetails":"Subprotocol B was activated on August 12, 2015. Fifty-nine patients were assigned to Subprotocol B after screening, all from screening cohort. Of the 59 patients, 40 patients were enrolled in arm B between August 2015 and June 2017."}